NCT06106802 2026-02-23Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentSamsung Medical CenterPhase 2 Recruiting47 enrolled
NCT06031688 2026-01-23Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2 Recruiting56 enrolled